Difficulty: Medium
Average Score: 93%
Practice
The best treatment option for step-6 severe persistent asthma in a 6-year-old boy is
Correct answer
D
Rationale
In the management of step-6 severe persistent asthma in a 6-year-old boy, the best treatment option is D) high-dose inhaled corticosteroids with long-acting B-agonist and oral corticosteroids along with omalizumab therapy. This comprehensive approach is necessary to address the severity of the condition and achieve optimal control.
High-dose inhaled corticosteroids with long-acting B-agonists help to reduce inflammation and provide bronchodilation. Oral corticosteroids may be required during exacerbations to control symptoms and prevent further complications. Omalizumab, a monoclonal antibody, is recommended for children with severe allergic asthma to target specific immune responses.
The other options are suboptimal for step-6 severe persistent asthma. Option A lacks the addition of oral corticosteroids and omalizumab, which are crucial for severe cases. Option B includes a leukotriene receptor antagonist instead of omalizumab, which may not be as effective in severe asthma. Option C suggests low-dose inhaled corticosteroids, which are insufficient for managing severe persistent asthma in this age group.
Educationally, understanding the stepwise approach to asthma management in children is vital for healthcare providers caring for pediatric patients. It highlights the importance of individualized treatment plans based on disease severity and the need for a multidisciplinary approach in managing complex cases like severe persistent asthma.
High-dose inhaled corticosteroids with long-acting B-agonists help to reduce inflammation and provide bronchodilation. Oral corticosteroids may be required during exacerbations to control symptoms and prevent further complications. Omalizumab, a monoclonal antibody, is recommended for children with severe allergic asthma to target specific immune responses.
The other options are suboptimal for step-6 severe persistent asthma. Option A lacks the addition of oral corticosteroids and omalizumab, which are crucial for severe cases. Option B includes a leukotriene receptor antagonist instead of omalizumab, which may not be as effective in severe asthma. Option C suggests low-dose inhaled corticosteroids, which are insufficient for managing severe persistent asthma in this age group.
Educationally, understanding the stepwise approach to asthma management in children is vital for healthcare providers caring for pediatric patients. It highlights the importance of individualized treatment plans based on disease severity and the need for a multidisciplinary approach in managing complex cases like severe persistent asthma.